JP2015517471A5 - - Google Patents

Download PDF

Info

Publication number
JP2015517471A5
JP2015517471A5 JP2015510577A JP2015510577A JP2015517471A5 JP 2015517471 A5 JP2015517471 A5 JP 2015517471A5 JP 2015510577 A JP2015510577 A JP 2015510577A JP 2015510577 A JP2015510577 A JP 2015510577A JP 2015517471 A5 JP2015517471 A5 JP 2015517471A5
Authority
JP
Japan
Prior art keywords
tumor
antitumor agent
inhibits
antitumor
angiogenin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015510577A
Other languages
English (en)
Other versions
JP2015517471A (ja
Filing date
Publication date
Priority claimed from AU2013204740A external-priority patent/AU2013204740C1/en
Application filed filed Critical
Publication of JP2015517471A publication Critical patent/JP2015517471A/ja
Publication of JP2015517471A5 publication Critical patent/JP2015517471A5/ja
Pending legal-status Critical Current

Links

Claims (8)

  1. アンギオゲニンを有効成分とする抗腫瘍剤
  2. 抗腫瘍剤が、腫瘍体積の減少、腫瘍増殖の阻害又は遅延、腫瘍進行の阻害、腫瘍の代謝活性の変化、腫瘍の休眠の誘発、転移の阻害又は抑制、腫瘍浸潤の阻害又は抑制、腫瘍重量の減少、腫瘍血管新生の抑制、疾患進行までの時間(TDP)の改善、及び/又は生存率の向上を含む、請求項1に記載の抗腫瘍剤
  3. アンギオゲニンを、アンギオゲニンを富化させたミルク抽出物として含有する、請求項1に記載の抗腫瘍剤
  4. さらに化学療法剤、放射線療法、又はその両方を併用する請求項1〜3のいずれかに記載の抗腫瘍剤
  5. さらに、化学保護剤を含有する請求項1〜4のいずれかに記載の抗腫瘍剤
  6. 経口投与用抗腫瘍剤である請求項1〜5のいずれかに記載の抗腫瘍剤
  7. 抗腫瘍栄養補助食品である請求項1〜6のいずれかに記載の抗腫瘍剤
  8. アンギオゲニンと化学療法剤とを含む組成物。
JP2015510577A 2012-05-10 2013-05-10 癌治療方法 Pending JP2015517471A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2012901918 2012-05-10
AU2012901918A AU2012901918A0 (en) 2012-05-10 Methods for treating cancer
AU2013204740 2013-04-12
AU2013204740A AU2013204740C1 (en) 2012-05-10 2013-04-12 Methods of treating cancer using angiogenin or an angiogenin agonist
PCT/AU2013/000478 WO2013166555A1 (en) 2012-05-10 2013-05-10 Methods of treating cancer using angiogenin or an angiogenin agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018023212A Division JP2018100288A (ja) 2012-05-10 2018-02-13 癌治療方法

Publications (2)

Publication Number Publication Date
JP2015517471A JP2015517471A (ja) 2015-06-22
JP2015517471A5 true JP2015517471A5 (ja) 2016-06-30

Family

ID=49549993

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015510577A Pending JP2015517471A (ja) 2012-05-10 2013-05-10 癌治療方法
JP2018023212A Pending JP2018100288A (ja) 2012-05-10 2018-02-13 癌治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018023212A Pending JP2018100288A (ja) 2012-05-10 2018-02-13 癌治療方法

Country Status (10)

Country Link
US (1) US9839676B2 (ja)
EP (1) EP2846820A4 (ja)
JP (2) JP2015517471A (ja)
CN (1) CN104470533A (ja)
AU (1) AU2013204740C1 (ja)
BR (1) BR112014027967A2 (ja)
CA (1) CA2872850A1 (ja)
NZ (1) NZ631749A (ja)
RU (1) RU2014149807A (ja)
WO (1) WO2013166555A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2303311B1 (en) 2008-05-14 2018-08-01 Agriculture Victoria Services Pty Ltd Angiogenin for use in treating skeletal muscle disorders
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist
ES2846153T3 (es) * 2014-03-06 2021-07-28 Univ Southern California Uso de régimen de inanición a corto plazo en combinación con inhibidores de cinasa para potenciar la eficacia y viabilidad de fármacos quimioterápicos tradicionales y revertir efectos secundarios de cinasas en células y tejidos normales

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2623509B1 (fr) 1987-11-19 1990-04-20 Centre Nat Rech Scient Proteine de 17 kd a action angiogenique, son procede d'isolement a partir de lait de mammiferes, compositions therapeutiques la contenant, procede de detection et/ou de dosage et reactifs immunologiques de detection et de dosage des angiogenines de mammiferes, de leurs homologues et de leurs fragments
CA2128111C (en) 1992-01-15 1998-06-16 Klaas Daniel Kussendrager Process for isolating lactoferrin and lactoperoxidase from milk and milk products, and products obtained by such process
ATE270111T1 (de) 1993-03-18 2004-07-15 Cytimmune Sciences Inc Zusammensetzung und methode zur reduktion der toxizität von biologisch-aktiven faktoren
JP3112637B2 (ja) 1994-09-30 2000-11-27 雪印乳業株式会社 骨強化剤
JP2974604B2 (ja) 1996-01-23 1999-11-10 雪印乳業株式会社 塩基性タンパク質組成物、塩基性ペプチド組成物及びその利用
JP3929088B2 (ja) 1996-06-20 2007-06-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
RU2110066C1 (ru) 1996-12-27 1998-04-27 Московский государственный университет прикладной биотехнологии Способ количественного определения ангиогенина в биологическом сырье
NL1005677C2 (nl) 1997-03-27 1998-09-29 Campina Melkunie Bv Werkwijze voor het winnen van groeifactoren, of een samenstelling die één of meer groeifactoren bevat, uit melk of een derivaat daarvan.
KR100236977B1 (ko) 1997-11-01 2000-01-15 윤재승 인간 상피세포 성장인자와 인간 안지오게닌의 융합독소단백질 및 그의 제조방법
CA2331620A1 (en) 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
CA2377435A1 (en) 1999-06-29 2001-01-04 J. Alexander Marchosky Compositions and methods for forming and strengthening bone
EP1217070A1 (en) 2000-12-22 2002-06-26 CellGenix Technologie Transfer GmbH Selective cytotoxic fusion proteins
TW200526779A (en) 2001-02-08 2005-08-16 Wyeth Corp Modified and stabilized GDF propeptides and uses thereof
RU2204262C2 (ru) 2001-07-06 2003-05-20 Московский государственный университет прикладной биотехнологии Способ получения биологически активного белкового концентрата, обогащенного панкреатической рибонуклеазой а, ангиогенином и лизоцимом, из молочного ультрафильтрата
CN1161467C (zh) * 2001-07-09 2004-08-11 中国人民解放军军事医学科学院生物工程研究所 抗肿瘤作用的融合蛋白及该蛋白的应用
JP4291967B2 (ja) 2001-11-08 2009-07-08 雪印乳業株式会社 皮膚コラーゲン産生促進剤
US20050037955A1 (en) 2001-11-27 2005-02-17 Hooper Laura Virginia Therapeutic protein and treatments
US7511012B2 (en) 2002-12-20 2009-03-31 Amgen Inc. Myostatin binding agents
JP4698935B2 (ja) 2003-05-07 2011-06-08 雪印乳業株式会社 皮膚コラーゲン産生促進剤
WO2004106491A2 (en) 2003-05-22 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Angiogenin-based hiv-1 therapies
US8114969B2 (en) 2003-10-01 2012-02-14 Isis Innovation, Ltd. Immunotoxin derived from a recombinant human autoantibody and method of using thereof
CA2542494A1 (en) 2003-10-15 2005-05-06 Bayer Healthcare Ag Tetrahydro-naphthalene and urea derivatives
WO2005072764A2 (en) 2004-01-16 2005-08-11 Novocell, Inc. Fibrin-bound angiogenic factors to stimulate vascularization of transplant site of encapsulated cells
US8147561B2 (en) 2004-02-26 2012-04-03 Endosphere, Inc. Methods and devices to curb appetite and/or reduce food intake
CA2558478A1 (en) 2004-03-02 2005-09-15 Acceleron Pharma Inc. Alk7 and myostatin inhibitors and uses thereof
CA2570570A1 (en) * 2004-06-22 2006-01-05 Pro-Pharmaceuticals, Inc. Compositions and methods for the co-delivery of anti-cancer drugs, anti-angiogenic drugs, and a polysaccharide
GB0425625D0 (en) 2004-11-22 2004-12-22 Royal College Of Surgeons Ie Treatment of disease
US20060251739A1 (en) 2005-05-04 2006-11-09 National Yang-Ming University Composition and method for treating autoimmune disease and mucosal disorder
US20090036369A1 (en) 2005-07-26 2009-02-05 Kirin Pharma Kabushiki Kaisha Anti-tumor agents comprising r-spondins
WO2007023479A2 (en) 2005-08-23 2007-03-01 Royal College Of Surgeons In Ireland Treatment of central nervous system injury
CN104844713B (zh) 2005-11-23 2021-05-14 阿塞勒隆制药公司 Activin-ActRIIa拮抗剂及其促进骨骼生长的应用
EP1976987B1 (en) 2005-12-21 2012-06-27 Viventia Biotechnologies Inc. Cancer-associated Scratch variant
EP2046799B1 (en) 2006-04-26 2017-07-19 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
US8021659B2 (en) 2006-04-28 2011-09-20 Naidu Lp Coenzyme Q10, lactoferrin and angiogenin compositions and uses thereof
US20070275036A1 (en) 2006-05-18 2007-11-29 Celldyne Biopharma, Llc Avian follistatin product
EP2049151A4 (en) 2006-07-17 2010-03-24 Quintessence Biosciences Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
AU2007317200B8 (en) 2006-11-10 2012-02-02 Agriculture Victoria Services Pty Ltd. Process for the preparation of angiogenin
US7601689B2 (en) 2007-04-12 2009-10-13 Naidu Lp Angiogenin complexes (ANGex) and uses thereof
US20100190722A1 (en) 2007-09-11 2010-07-29 Dorian Bevec Substance p and thyrotropin releasing hormone for therapeutic applications
AU2013204721B2 (en) 2008-05-14 2016-08-18 Agriculture Victoria Services Pty Ltd Methods for treating cachexia
EP2307044A4 (en) * 2008-05-14 2011-10-05 Agriculture Victoria Serv Pty ORAL ADMINISTRATIVE DOSAGE FORMS COMPRISING ANGIOGENIN AND USES THEREOF
EP2303311B1 (en) * 2008-05-14 2018-08-01 Agriculture Victoria Services Pty Ltd Angiogenin for use in treating skeletal muscle disorders
CN102088862A (zh) 2008-05-14 2011-06-08 维多利亚农业服务控股公司 血管生成素富集的乳级分
EP2501411A4 (en) 2009-11-18 2013-07-03 Murray Goulburn Coop Co Ltd PROCESS FOR IMPROVED ORAL ADMINISTRATION
JP2013511261A (ja) 2009-11-18 2013-04-04 マリー ゴールバーン シーオー−オペレイティブ シーオー.リミテッド 組換え微生物
US20120331575A1 (en) 2009-11-18 2012-12-27 Agriculture Victoria Services Pty Ltd Transgenic non-human animals
US9855320B2 (en) 2011-10-06 2018-01-02 Chung-Ang University Industry-Academic Cooperation Foundation Angiogenin for treatment of glaucoma
AU2013204740C1 (en) 2012-05-10 2015-10-01 Agriculture Victoria Services Pty Ltd Methods of treating cancer using angiogenin or an angiogenin agonist

Similar Documents

Publication Publication Date Title
JP2015078230A5 (ja)
PH12015500686A1 (en) Nicotine composition
JP2011079858A5 (ja)
JP2012255026A5 (ja)
WO2016080810A3 (ko) 바이구아나이드 화합물 및 이의 용도
MX2015013845A (es) Polvos secos de tiotropio.
JP2009542581A5 (ja)
JP2015517471A5 (ja)
JP2014506233A5 (ja)
RU2017141536A (ru) Замещенные производные индол-5-ола и их терапевтические применения
JP2015507020A5 (ja)
PH12014502619A1 (en) Novel dosage and formulation
JP2014530181A5 (ja)
WO2012151279A3 (en) Induction of il-12 using immunotherapy
JP2015522025A5 (ja)
MX2015009891A (es) Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion.
ZA201404068B (en) The use of silver(i) complexes as active pharmaceutical ingredients (api's) iincluding anticancer agents
RU2014149807A (ru) Способы лечения злокачественных новообразований с помощью ангиогенина или агониста ангиогенина
JP2013079218A5 (ja)
MX2017004633A (es) Formulaciones que contienen tiotropio, aminoacidos y acidos, y metodos de estas.
JP2015120650A5 (ja)
Mizuta et al. Hepatocellular carcinoma and vitamin K2
LV15003A (lv) Farmaceitiska kompozīcija ķermeņa masas pieauguma kontrolei
TH87455B (th) ผงชนิดแตกตัวในปากซึ่งประกอบรวมด้วยไซโลสทาซอล
WO2020018049A3 (en) Lipid nanoparticles loaded with ceranib-2 as anticancer agents